{
    "over_18_start_BMI_over_27":
        {
            "header": "Verify Prescriber and Patient Documentation",
            "items": [
                {
                    "text": "Document that member is actively enrolled in a weight-loss program that involves a reduced calorie diet and increased physical activity adjunct to therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission." 
                },
                {
                    "text": "Document Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s).",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "text": "Document that the dose prescribed does not exceed 0.25mg in week 1-4, 0.5mg in weeks 5-8, 1mg in weeks 9-12 and 1.7mg in weeks 13-16.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                }
              
            ]
        },
    "over_18_start_BMI_over_30":
        {
            "header": "Verify Prescriber and Patient Documentation",
            "items": [
                {
                    "text": "Document that member is actively enrolled in a weight-loss program that involves a reduced calorie diet and increased physical activity adjunct to therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission." 
                },
                {
                    "text": "Document Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s).",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "text": "Document that the dose prescribed does not exceed 0.25mg in week 1-4, 0.5mg in weeks 5-8, 1mg in weeks 9-12 and 1.7mg in weeks 13-16.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                }
              
            ]
        },

    "first_continuation":
        {
            "header": "Prepare Patient Documentation",
            "items": [
                {
                    "text": "Member has previously received medication via Centene benefit or is enrolled in a state and product with continuity of care regulations.",
                    "validation": "Stop and submit a prior authorization following the criteria for start of therapy." 
                },
                {
                    "text": "Document Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s).",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "text": "Dose does not exceed 2.4 mg once weekly or a temporary dose reduction to 1.7mg for a maximum of 4 weeks.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "text": "Document that member has lost â‰¥ 5% of baseline body weight (adults).",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "text": "Document that member is actively enrolled in a weight loss program that involves a reduced calorie diet and increased physical activity adjunct to therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                }
            ]
        },
      "second_continuation":
        {
            "header": "Prepare Patient Documentation",
            "items": [
                {
                    "text": "Member has previously received medication via Centene benefit or is enrolled in a state and product with continuity of care regulations.",
                    "validation": "Stop and submit a prior authorization following the criteria for start of therapy." 
                },
                {
                    "text": "Document Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s).",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "text": "Dose does not exceed 2.4 mg once weekly or a temporary dose reduction to 1.7mg for a maximum of 4 weeks.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "text": "Document member has lost weight and/or maintained 5% weight loss on therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "text": "Document that member is actively enrolled in a weight loss program that involves a reduced calorie diet and increased physical activity adjunct to therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                }
            ]
        },
    "below_18_initiation":
        {
            "header": "Verify Prescriber and Patient Documentation",
            "items": [
                {
                    "text": "Document that the requested drug will be used with a reduced-calorie diet and increased physical activity for chronic weight management.",
                    "validation": "Stop and contact provider to document this in the patient's chart."
                },
                {
                    "text": "Document that the patient has participated in a comprehensive weight management program that encourages behavioral modification, reduced-calorie diet, and increased physical activity with continuing follow-up for at least 6 months prior to using drug therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart."
                },
                {
                    "text": "Document that member is actively enrolled in a weight loss program that involves a reduced calorie diet and increased physical activity adjunct to therapy",
                    "validation": "Stop and contact provider to document this in the patient's chart."
                },
                {
                    "text": "Document that the patient has an initial body mass index (BMI) in the 95th percentile or greater standardized for age and sex (obesity).",
                    "validation": "Stop and contact provider to document this in the patient's chart."
                },
                {
                    "text": "Document Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s).",
                    "validation": "Stop and contact provider to document this in the patient's chart."
                },
                {
                    "text": "Document that the dose prescribed does not exceed 0.25mg in week 1-4, 0.5mg in weeks 5-8, 1mg in weeks 9-12 and 1.7mg in weeks 13-16.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                }
            ]
        }
}
